K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology

• Published in: Biochemical and biophysical research communications 2017-03, Vol.484 (3), p.605-611
• Main Authors: Sakamoto, Kotaro, Kamada, Yusuke, Sameshima, Tomoya, Yaguchi, Masahiro, Niida, Ayumu, Sasaki, Shigekazu, Miwa, Masanori, Ohkubo, Shoichi, Sakamoto, Jun-ichi, Kamaura, Masahiro, Cho, Nobuo, Tani, Akiyoshi
• Format: Article
• Language: English
• Subjects: 60 APPLIED LIFE SCIENCES; AMINO ACIDS; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Bacteriophage T7; BACTERIOPHAGES; Binding Sites; Cell Line, Tumor; CELL PROLIFERATION; Drug Discovery - methods; Enzyme Activation - drug effects; ENZYME ACTIVITY; G12D-mutation; Humans; INHIBITION; Inhibitor; K-Ras; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Peptide; Peptide Library; PEPTIDES; Phage display; PLANT GROWTH; Protease Inhibitors - administration & dosage; Protease Inhibitors - chemistry; Protease Inhibitors - metabolism; Protein Binding; Protein Interaction Mapping - methods; Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors; Proto-Oncogene Proteins p21(ras) - metabolism; RANDOMNESS
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2017.01.147

Amino-acid mutations of Gly12 (e.g. G12D, G12V, G12C) of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras), the most promising drug target in cancer therapy, are major growth drivers in various cancers. Although over 30 years have passed since the discovery of these mutations in most cancer patients, effective mutated K-Ras inhibitors have not been marketed. Here, we report novel and selective inhibitory peptides to K-Ras(G12D). We screened random peptide libraries displayed on T7 phage against purified recombinant K-Ras(G12D), with thorough subtraction of phages bound to wild-type K-Ras, and obtained KRpep-2 (Ac-RRCPLYISYDPVCRR-NH2) as a consensus sequence. KRpep-2 showed more than 10-fold binding- and inhibition-selectivity to K-Ras(G12D), both in SPR analysis and GDP/GTP exchange enzyme assay. KD and IC50 values were 51 and 8.9 nM, respectively. After subsequent sequence optimization, we successfully generated KRpep-2d (Ac-RRRRCPLYISYDPVCRRRR-NH2) that inhibited enzyme activity of K-Ras(G12D) with IC50 = 1.6 nM and significantly suppressed ERK-phosphorylation, downstream of K-Ras(G12D), along with A427 cancer cell proliferation at 30 μM peptide concentration. To our knowledge, this is the first report of a K-Ras(G12D)-selective inhibitor, contributing to the development and study of K-Ras(G12D)-targeting drugs. •The first K-Ras(G12D)-selective inhibitory peptides were generated.•These peptides showed more than 10-fold binding- and inhibition-selectivity to K-Ras(G12D) in compared to wild type K-Ras.•The peptide KRpep-2d suppressed downstream signal of K-Ras(G12D) and cell proliferations of cancer cell line A427.